浸润性黏液腺癌分子机制及临床治疗研究进展  

Advances on Molecular Mechanism and Clinical Treatment in Invasive Mucinous Adenocarcinoma

作　　者：施旻均 叶波[1] Minjun SHI;Bo YE(Department of Thoratic Surgery,Shanghai Chest Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200030,China)

机构地区：[1]上海市胸科医院,上海交通大学医学院附属胸科医院胸外科,上海200030

出　　处：《中国肺癌杂志》2024年第9期685-690,共6页Chinese Journal of Lung Cancer

摘　　要：浸润性黏液腺癌(invasive mucinous adenocarcinoma,IMA)是肺腺癌的一种特殊亚型,其发病率占全部肺腺癌的2%-10%。IMA的治疗首选外科手术,传统化疗药物及靶向治疗药物对该疾病的疗效较差。与其他非黏液性肺腺癌亚型相比,IMA具有独特的预后、影像学及分子学特征。IMA的发病率极低,因此胸外科医生容易对此病缺乏认识,误诊为肺炎、结核等良性疾病。本文对IMA的影像学、临床病理特征、治疗方式及预后进行综述与讨论。Invasive mucinous adenocarcinoma(IMA)is a special type of lung adenocarcinoma that accounts for 2%to 10%of all lung adenocarcinoma.Surgical treatment is preferred for IMA,and traditional chemotherapy drugs and targeted therapy drugs have poor efficacy in this disease.IMA has unique prognostic,imaging and molecular features.The incidence of IMA is very low,so thoracic surgeons may lack of knowledge to the disease and misdiagnose it as benign diseases such as pneumonia and tuberculosis.This article reviews and discusses the imaging,clinicopathological features,treatment methods and prognosis of IMA.

关 键 词：肺肿瘤 浸润性黏液腺癌 分子机制 治疗 

分 类 号：R734.2[医药卫生—肿瘤]